Alexan (cytarabine) solution 50 mg/ml. 20 ml. (1000 mg.) vial №1


Manufacturer: Hungary



Achievement and maintenance of remission in acute non-lymphoblastic leukemia in adults and children. Treatment of other types of leukemia, such as acute lymphocytic leukemia, chronic myeloblastic leukemia (blast crisis).
Prevention or treatment of leukemia meningitis intrathecally as monotherapy or in combination with other drugs (methotrexate, hydrocortisone).
Alexan can be used as monotherapy or in combination with other Antineoplastic agents; better results are usually achieved with complex treatment. The remissions induced by the drug Alexan are short-lived without further supportive therapy.
Leukemia therapy with high risk of complications, refractory leukemia and recurrence of acute leukemia regardless of concomitant use of high-dose anticancer chemotherapeutic agents.
In combination therapy (LSA2L2) for the treatment of non-Hodgkin’s lymphoma in children.
Drugs, the active substance of which is cytarabine, have been experimentally used to treat various types of tumors. In general, a small number of patients with solid tumors had a positive response to treatment.
Suppression of milk secretion and relief from breast swelling and chest pain were observed in approximately 85% of women during lactation when administered with a total dose of 4 mg cabergoline for two days. Breastfeeding cases in 10 days are infrequent (approximately 2% of cases).